Amicus Therapeutics Inc
$ 14.49
0.21%
24 Apr - close price
- Market Cap 4,549,870,000 USD
- Current Price $ 14.49
- High / Low $ 14.50 / 14.49
- Stock P/E N/A
- Book Value 0.88
- EPS -0.09
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.12 %
- 52 Week High 14.50
- 52 Week Low 5.51
About
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing and delivering drugs for people living with rare metabolic diseases. The company is headquartered in Philadelphia, Pennsylvania.
Analyst Target Price
$14.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-04 | 2025-07-31 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-08 | 2023-08-08 | 2023-05-10 |
| Reported EPS | 0.1 | 0.06 | -0.08 | 0.03 | 0.09 | -0.02 | -0.05 | -0.16 | -0.11 | -0.07 | -0.15 | -0.18 |
| Estimated EPS | 0.065 | 0.03 | -0.11 | -0.07 | 0.0911 | -0.01 | -0.06 | -0.07 | -0.06 | -0.08 | -0.12 | -0.15 |
| Surprise | 0.035 | 0.03 | 0.03 | 0.1 | -0.0011 | -0.01 | 0.01 | -0.09 | -0.05 | 0.01 | -0.03 | -0.03 |
| Surprise Percentage | 53.8462% | 100% | 27.2727% | 142.8571% | -1.2075% | -100% | 16.6667% | -128.5714% | -83.3333% | 12.5% | -25% | -20% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FOLD
2026-04-24 19:39:56
Amicus Therapeutics (FOLD) is garnering investor interest due to recent positive share price performance and its rare disease portfolio. Analysts currently peg its fair value at $14.50, which is closely aligned with its current trading price of $14.46, suggesting it is slightly undervalued. The company's growth prospects are driven by expanding patient identification for Fabry and Pompe diseases, although potential risks from new competitors or pricing pressures exist.
2026-04-24 14:09:56
Amicus Therapeutics (FOLD) has garnered investor attention due to recent positive share price performance and its rare disease portfolio, particularly for Fabry and Pompe diseases. The stock is currently trading near its analyst target of $14.50, which suggests it is undervalued. The company's valuation is driven by expanding patient identification and diagnostic pathways in rare diseases, which are expected to lead to sustained revenue growth.
2026-04-23 21:09:45
BioMarin Pharmaceutical Inc. has received French regulatory clearance for its merger with Amicus Therapeutics, satisfying the final condition for the transaction. The merger is now expected to close on April 27, 2026, with BioMarin showing strong financial health for the acquisition. This development follows recent news for BioMarin, including board changes, strategic decisions on drug development, and analyst ratings.
2026-04-23 20:09:45
Amicus Therapeutics (NASDAQ: FOLD) has received French regulatory clearance for its merger with BioMarin Pharmaceutical, satisfying the final major condition for the acquisition. The merger, under which Amicus will become a wholly-owned subsidiary of BioMarin, is now expected to close on April 27, 2026. This development removes a significant hurdle, though the companies note that forward-looking statements are subject to various risks and uncertainties.
2026-04-23 20:09:45
Amicus Therapeutics has received French foreign investment clearance for its merger with BioMarin, satisfying a key condition of the merger agreement. The companies anticipate the deal to officially close on April 27, 2026. This clearance marks the final condition met, other than standard closing-time conditions.
2026-04-23 19:39:56
BioMarin Pharmaceutical has announced its intention to acquire Amicus Therapeutics for $4.8 billion, aiming to strengthen its rare disease treatment portfolio. Amicus Therapeutics, with operations in Philadelphia, specializes in treatments for rare genetic disorders and would significantly expand BioMarin's therapeutic offerings, particularly in Pompe disease. The acquisition is expected to create a leading global rare disease company with a broader pipeline and enhanced market position.
